Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT.
Mickelson
D M
DM
Department of Internal Medicine, The Ohio State University, Columbus, OH, USA. Deborah.mickelson@osumc.edu
Sproat
L
L
Dean
R
R
Sobecks
R
R
Rybicki
L
L
Kalaycio
M
M
Pohlman
B
B
Sweetenham
J
J
Andresen
S
S
Bolwell
B
B
Copelan
E A
EA
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002066:Busulfan / Q000009:adverse effects / Q000627:therapeutic use; D046528:Chimerism; D003131:Combined Modality Therapy / Q000009:adverse effects; D005260:Female; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000009:adverse effects / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology* / Q000378:metabolism; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014183:Transplantation, Heterologous; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D014916:Whole-Body Irradiation / Q000009:adverse effects; D055815:Young Adult
D000970:Antineoplastic Agents; D019653:Myeloablative Agonists; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine